August 19, 2019
Angel-Funded Siamab Completes $202 Million Exit with Large Commercial-Stage Biopharma
Siamab Therapeutics, Inc., a biopharmaceutical company developing novel glycan-targeted cancer therapeutics, has entered into a strategic agreement valued at up to $202 million with an undisclosed, large commercial-stage biopharmaceutical company ...
June 12, 2019
Harbour BioMed and Erasmus MC Sign MoU to Advance Next-Generation Immuno-oncology, and Immunology Drug Discovery and Clinical Development
The MoU was signed during the official, 40thanniversary celebration ceremony of the Shanghai-Rotterdam Sister City Relationship.
May 9, 2019
Labshares Newton Selects Savran Technologies as Winner of First Launch@Labshares Competition Valued at $50K
Second Launch@Shares Competition Announced in Collaboration with MTTC/MALSI Conference and MassBio’s MassCONNECT Program
.png)
.avif)
